Development of a novel hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening and quantification of neutralization antibodies, viral variants, and antiviral drugs
B. Hetrick, S. He, L. D. Chilin, D. Dabbagh, F. Alem, A. Narayanan, A. Luchini, T. Li, X. Liu, J. Copeland, A. Pak, T. Cunningham, L. Liotta, E. Petricoin, A. Andalibi, Y. Wu
This paper develops a hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening of neutralizing antibodies, viral variants, and antiviral drugs, showing increased infectivity of variants and enhanced neutralization by post-vaccination serum.
bioRxiv · Dec 22, 2020 · PreprintMicrobiology